Colorectal carcinoma is the third most common cause of cancer death in the United States, with 135,000 new cases and 55,000 deaths annually. Ultimately, two-thirds (99,000) of all patients with colorectal cancer will develop metastasis to the liver and other organs in their life span, making metastatic colorectal cancer the second leading cause of cancer-related death in North America. The optimal management of these patients has become increasingly complex with the myriad of treatment options that are available. Because the timing of any therapy (surgery, chemotherapy, or others) has become integral to the success of the treatment, a collaborative approach involving multiple specialties is needed for the best patient outcome. Defined clinical and pathologic determinants of outcome have been demonstrated to effect the overall and disease-free survival of patients with metastatic colorectal cancer. Understanding of these determinants remains essential to any treating physician and has lead to significant paradigm shifts in the management of patients with metastatic colorectal cancer.
Get full access to this article
View all access options for this article.
References
1.
BakalakosE.A., KimJ.A., YoungD.C., MartinE.W.Jr.Determinants of survival following hepatic resection for metastatic colorectal cancer.World J Surg1998; 22: 399–404.
GilbertH.A., KaganA.R.Metastases: Incidence, detection, and evaluation without histologic confirmation.Weiss1976; L: 385–405.
7.
FongY., FortnerJ., SunR.L.Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.Ann Surg1999; 230: 309–18.
8.
GonenM., HummerA., ZervoudakisA.Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer.J Clin Oncol2003; 21: 406–12.
9.
NagakuraS., ShiraiY., YokoyamaN.Major hepatic resection reduces the probability of intrahepatic recurrences following resection of colorectal carcinoma liver metastases.Hepatogastroenterology2003; 50: 779–83.
10.
YanD.B., ClinganP., MorrisD.L.Hepatic cryotherapy and regional chemotherapy with or without resection for liver metas-tases from colorectal carcinoma: how many are too many?Cancer2003; 98: 320–30.
11.
MauchleyD.C., LyngeD.C., LangdaleL.A.Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer.Am J Surg2005; 189: 512–7.
12.
ShoupM., GonenM., D'AngelicaM.Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection.J Gastrointest Surg2003; 7: 325–30.
13.
AbdallaE.K., BarnettC.C., DohertyD.Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization.Arch Surg2002; 137: 675–80.
14.
ScheeleJ., Altendorf-HofmannA.Resection of colorectal liver metastases.Langenbecks Arch Surg1999; 384: 313–27.
15.
RuersT.J., LangenhoffB.S., NeelemanN.Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.J Clin Oncol2002; 20: 388–95.
16.
StrasbergS.M., DehdashtiF., SiegelB.A.Survival of patients evaluated by FDG-PET before hepatic resection for meta-static colorectal carcinoma: a prospective database study.Ann Surg2001; 233: 293–9.
17.
Schussler-FiorenzaC.M., MahviD.M., NiederhuberJ.Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases.J Gastrointest Surg2004; 8: 150–7.
18.
RodgersM.S., CollinsonR., DesaiS.Risk of dissemination with biopsy of colorectal liver metastases.Dis Colon Rectum2003; 46: 454–8.
19.
JonesO.M., ReesM., JohnT.G.Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection.Br J Surg2005; 92: 1165–8.
20.
ThalerK., KannegantiS., KhajancheeY.The evolving role of staging laparoscopy in the treatment of colorectal hepatic metastasis.Arch Surg2005; 140: 727–34.
21.
LoC.M., LaiE.C., LiuC.L.Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma.Ann Surg1998; 227: 527–32.
22.
CalleryM.P., StrasbergS.M., DohertyG.M.Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy.J Am Coll Surg1997; 185: 33–9.
23.
GervazP., Pak-artR., NivatvongsS.Colorectal adenocarcinoma in cirrhotic patients.J Am Coll Surg2003; 196: 874–9.
24.
KemenyN., HuangY., CohenA.M.Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.N Engl J Med1999; 341: 2039–48.
25.
LorenzM., Staib-SeblerE., GogC.Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.Zentralbl Chir2003; 128: 87–94.
26.
OnaitisM., MorseM., HurwitzH.Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases.Ann Surg2003; 237: 782–8.
27.
TanakaK., AdamR., ShimadaH.Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver.Br J Surg2003; 90: 963–9.
28.
TehC.S., OoiL.L.Hepatic resection for colorectal metastases to the liver: The National Cancer Centre/Singapore General Hospital experience.Ann Acad Med Singapore2003; 32: 196–204.
29.
AbdallaE.K., VautheyJ.N., EllisL.M.Recurrence and outcomes following hepatic resection, radio frequency ablation, and combined resection/ablation for colorectal liver metastases.Ann Surg2004; 239: 818–25.
30.
ChuaH.K., SondenaaK., TsiotosG.G.Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases.Dis Colon Rectum2004; 47: 1310–6.
31.
LaurentC., SaC.A., RullierE.Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis.J Am Coll Surg2004; 198: 884–91.
32.
NagashimaI., TakadaT., MatsudaK.A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection.J Hepatobiliary Pancreat Surg2004; 11: 79–83.
33.
ShimadaH., TanakaK., MasuiH.Results of surgical treatment for multiple (≥5 nodules) bi-lobar hepatic metastases from colorectal cancer.Langenbecks Arch Surg2004; 389: 114–21.
34.
TanakaK., ShimadaH., OhtaM.Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer.World J Surg2004; 28: 482–7.
35.
TocchiA., MazzoniG., BrozzettiS.Hepatic resection in stage IV colorectal cancer: prognostic predictors of outcome.Int J Colorectal Dis2004; 19: 580–5.
36.
CouinaudC.Le Foie: Etudes Anatomiques et Chirurgicales.Paris: Masson & Cie, 1957.
37.
MartinR.C.G., PatyP., FongY.Simultaneous Liver and Colorectal Resections are Safe for Synchronous Colorectal Liver Metastasis, J Am Coll Surg2003; 197: 233–41.
38.
NordlingerB., QuilichiniM.A., ParcR.Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients.Ann Surg1987; 205: 256–63.
39.
StadlerJ., HolscherA.H., AdolfJ.Intraoperative ultrasonographic detection of occult liver metastases in colorectal cancer.Surg Endosc1991; 5: 36–40.
40.
RohM.S.Hepatic resection for colorectal liver metastases.Hematol Oncol Clin North Am1989; 3: 171–81.
41.
KokudoN., MikiY., SugaiS.Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection.Arch Surg2002; 137: 833–40.
42.
MelendezJ.A., ArslanV., FischerM.E.Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction.J Am Coll Surg1998; 187: 620–5.
43.
KoobyD.A., JarnaginW.R.Surgical management of hepatic malignancy.Cancer Invest2004; 22: 283–303.
FujitaS., AkasuT., MoriyaY.Resection of synchronous liver metastases from colorectal cancer.Jpn J Clin Oncol2000; 30: 7–11.
46.
NakamuraS., YokoiY., SuzukiS.Results of extensive surgery for liver metastases in colorectal carcinoma.Br J Surg1992; 79: 35–8.
47.
GoughD.B., DonohueJ.H., TrastekV.A., NagorneyD.M.Resection of hepatic and pulmonary metastases in patients with colorectal cancer.Br J Surg1994; 81: 94–6.
48.
RegnardJ.F., GrunenwaldD., SpaggiariL.Surgical treatment of hepatic and pulmonary metastases from colorectal cancers.Ann Thorac Surg1998; 66: 214–8.
49.
AmbiruS., MiyazakiM., ItoH.Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma.Cancer1998; 82: 274–8.
50.
MurataS., MoriyaY., AkasuT.Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma.Cancer1998; 83: 1086–93.
51.
RossiS., Di StasiM., BuscariniE.Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer.AJR Am J Roentgenol1996; 167: 759–68.
52.
CurleyS.A., IzzoF., DelrioP.Radio frequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients.Ann Surg1999; 230: 1–8.
53.
WoodT.F., RoseD.M., ChungM.Radio frequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications.Ann Surg Oncol2000; 7: 593–600.
54.
SipersteinA., GarlandA., EngleK.Local recurrence after laparoscopic radio frequency thermal ablation of hepatic tumors.Ann Surg Oncol2000; 7: 106–13.
55.
De BaereT., EliasD., DromainC.Radio frequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year.AJR Am J Roentgenol2000; 175: 1619–25.
56.
MachiJ.Radio frequency ablation for multiple hepatic metastases.Ann Surg Oncol2001; 8: 379–80.
57.
CurleyS.A., MarraP., BeatyK.Early and late complications after radio frequency ablation of malignant liver tumors in 608 patients.Ann Surg2004; 239: 450–8.
58.
BilchikA.J., RoseD.M., AllegraD.P.Radio frequency ablation: a minimally invasive technique with multiple applications.Cancer J Sci Am1999; 5: 356–61.
59.
PearsonA.S., IzzoF., FlemingR.Y.Intraoperative radio frequency ablation or cryoablation for hepatic malignancies.Am J Surg1999; 178: 592–9.
60.
Meta-Analysis Group in Cancer.Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.J Natl Cancer Inst1996; 88: 252–8.
61.
MartinR.C.G., EdwardsM.J., McMastersK.M.Morbidity of Adjuvant Hepatic Arterial Infusion Pump Chemotherapy in the Management of Colorectal Cancer Metastatic to the Liver.Am J Surg2004; 188: 714–21.
62.
GrayB., Van HazelG., HopeM.Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.Ann Oncol2001; 12: 1711–20.
63.
Van HazelG., BlackwellA., AndersonJ.Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.J Surg Oncol2004; 88: 78–85.
64.
LimL., GibbsP., YipD.Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies.Intern Med J2005; 35: 222–7.
65.
DawsonL.A., LawrenceT.S.The role of radiotherapy in the treatment of liver metastases.Cancer J2004; 10: 139–44.
66.
AdamR., DelvartV., PascalG.Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.Ann Surg2004; 240: 644–57.
67.
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators.Efficacy of adjuvant fluorouracil and folinic acid in colon cancer.Lancet1995; 345: 939–44.
68.
MoertelC.G., FlemingT.R., MacdonaldJ.S.Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.Ann Intern Med1995; 122: 321–6.
69.
HallerD.G., LefkopoulouM., MacdonaldJ.S., MayerR.S.Some considerations concerning the dose and schedule of 5FU and leucovorin: toxicities of two dose schedules from the intergroup colon adjuvant trial (INT-0089).Adv Exp Med Biol1993; 339: 51–4.
70.
HallerD.G., CatalanoP.J., MacDonaldJ.S.Flourouracil (FU), leucovorin (LV), and levamisole (LEV) adjuvant therapy for colon cancer: five year report of INT-0089.Proc Am Soc Clin Oncol1998; 17: 982, 256a.
71.
GillS., LoprinziC.L., SargentD.J.Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?J Clin Oncol2004; 22: 1797–806.
72.
de GramontA., FigerA., SeymourM.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol2000; 18: 2938–47.
73.
CunninghamD., HumbletY., SienaS.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer.N Engl J Med2004; 351: 337–45.
74.
EllisL.M., CurleyS.A., GrotheyA.Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.J Clin Oncol2005; 23: 4853–5.
